These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12209732)

  • 1. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
    Feuer EJ; Mariotto A; Merrill R
    Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
    Brenner H; Arndt V
    J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
    Gilliland F; Becker TM; Smith A; Key CR; Samet JM
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
    Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
    BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
    Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
    Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
    Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
    Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
    J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
    Merrill RM; Stephenson RA
    J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.